SecBot SecBot
SC 13D/A ·Filed Nov 13, 2026

FMS

Fresenius Medical Care AG
BEARISH
Impact 5/10
Horizonweeks Processed3d 12h ago SEC0001140361-26-043717
Activist stake amendment (position change)
Actionable Insight ▼ Bearish

The 5% secondary offering by the controlling shareholder signals potential further monetization of the FMS stake over time. The 90-day lock-up provides near-term certainty on no additional overhang, but the stated portfolio optimization intent suggests further sales after the lock-up expire. Monitor for any additional SC 13D filings or announcements regarding further stake reductions.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$22.03
T+0 close · Nov 13, 2026 · via day close
Latest settled
−0.77%
T+1 · $21.86
Vs SPY
+1.14%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $22.03entry
  2. T+1 · 21h ago −0.77%α +1.14% · $21.86
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Fresenius SE & Co. KGaA, the controlling shareholder of Fresenius Medical Care AG (FMS), sold 13,443,240 shares (approximately 5.0% of FMS's outstanding shares) at EUR 39.00 per share for gross proceeds of EUR 524 million, reducing its stake from 25.01% to 20.9%. The sale is part of Fresenius KGaA's portfolio optimization strategy and is subject to a 90-day lock-up on further share sales.

Key Financial Metrics

Stake
20.9%
Investor
Fresenius SE & Co. KGaA

Key Facts

  • Fresenius KGaA sold 13,443,240 FMS shares at EUR 39.00 per share, gross proceeds EUR 524,286,360
  • Stake reduced from 25.01% (67,181,358 shares) to 20.9% (53,738,118 shares) of outstanding shares
  • Sale executed via accelerated bookbuild with BNP Paribas, BofA Securities, Deutsche Bank, and J.P. Morgan as joint bookrunners
  • Fresenius KGaA entered a 90-day lock-up on further share sales starting November 12, 2026
  • Fresenius KGaA stated the sale is part of a broader portfolio optimization strategy and may consider further alternatives regarding its FMS investment

Financial Impact

EUR 524 million gross proceeds from sale of 13,443,240 shares at EUR 39.00 each

dilutionownership structure

Risk Factors

  • Potential further share sales by Fresenius KGaA after the 90-day lock-up period ends
  • Overhang from the large block sale may pressure the stock in the near term
  • Reduced controlling shareholder commitment could signal strategic uncertainty

Market Snapshot

Exchange
OTC
Sector
Services-Misc Health & Allied Services, NEC
Analyst Consensus
21% bullish (29 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13D/A Filing (Primary)0001140361-26-043717
Document: ef20085475_ex99-3.htm0001140361-26-043717
Document: ef20085475_ex99-1.htm0001140361-26-043717
Document: 0001140361-26-043717-index-headers.html0001140361-26-043717
Document: 0001140361-26-043717-index.html0001140361-26-043717
Document: 0001140361-26-043717.txt0001140361-26-043717

Track record

16 reports on FMS

Performance horizon

2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +3.43% at T+60 after the Apr 7, 2026 report. 2 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13D/A Bearish 5/10 Viewing Entry $22.03 Now $21.86 +0.77% settles Nov 20
  2. Nov 9, 20267d ago 6-K Neutral 2/10 Entry $22.95 to $21.86 Now $21.86 −4.75% ▼ −4.75% −3.06% vs SPY
  3. Nov 3, 202613d ago 6-K Bearish 6/10 No price data
  4. Nov 3, 202613d ago 6-K Bearish 5/10 Entry $21.73 to $22.74 Now $21.86 −0.60% ▼ −4.65% −5.24% vs SPY
  5. Oct 30, 202618d ago Court Ruling Neutral 4/10 Entry $22.61 to $22.95 Now $21.86 −3.32% ▲ +1.50% +1.43% vs SPY
  6. Oct 7, 20265w ago 6-K Neutral 3/10 Entry $20.69 to $21.54 Now $21.86 +5.65% ▲ +4.11% +5.09% vs SPY
  7. Sep 25, 20267w ago 6-K Bearish 5/10 Entry $22.69 to $22.25 Now $21.86 +3.66% ▲ +1.94% +1.72% vs SPY
  8. Sep 1, 202611w ago Court Ruling Neutral 1/10 Entry $22.65 to $22.23 Now $21.86 −3.49% ▼ −1.85% −0.90% vs SPY
  9. Aug 31, 202611w ago GOVT-CONTRACT Neutral 3/10 Entry $22.74 to $22.33 Now $21.86 −3.87% ▼ −1.80% −1.88% vs SPY
  10. Aug 31, 202611w ago Court Ruling Neutral 4/10 Entry $22.74 to $22.33 Now $21.86 −3.87% ▼ −1.80% −1.88% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 5h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026